Mirada Medical Showcases Imaging Technologies At ASTRO Conference In San Diego
Mirada Medical Limited, the fast growing international company focused on advanced oncology imaging, is showcasing a variety of powerful imaging technologies at the annual conference of the American Society of Radiation Oncology (ASTRO) in San Diego, Oct. 31st to Nov. 3rd. Mirada will be based at Booth 1813.
The Oxford, UK based company is showing a range of applications which will complement the treatment planning process and deliver new insight in treatment response assessment.
Central to the presentation will be imaging workflows to support adaptive radiation therapy through the software assisted assessment of anatomical change as a result of treatment. Mirada's technology leading deformable image registration technologies will power applications such as contour warping from planning to re-planning CT.
The same registration technologies also enable non CT modalities such as MRI and PET to be seamlessly integrated into the planning process, again through the utilization of deformable image registration. Mirada's products have proven interoperability with all major treatment planning.
Mirada will also showcase full integration of gated CT/PET data within its XD3 image analysis application.
Mirada's Chief Executive, Hugh Bettesworth said "Powerful multi-modal deformable registration is the engine inside many of the most exciting new applications for radiation oncology. Mirada is delighted to be at ASTRO this year, where we will show what we believe is the world's leading registration technology powering the next generation of RT workflows. Users of such workflows will save time, and potentially gain valuable new insight as they undertake the complex task of planning and delivering potentially life saving therapies."
About Mirada Medical
Mirada Medical Limited develops internationally recognised medical imaging analysis applications that provide clinicians with advanced software applications for the quantification of images which are typically used in cancer diagnosis and treatment response assessment. Mirada Medical's technology has broad applicability across nuclear medicine, diagnostic radiology, radiation oncology and medical oncology. Mirada Medical also markets products in neurology and cardiology. Mirada specialises in offering comprehensive and quantifiable analysis for the diagnosis, staging, treatment planning and assessment of treatment response in oncology. Mirada's advanced technology allows medical images acquired using MRI, CT, SPECT or PET scanners to be combined into one, a process known as image fusion. Image fusion is useful in clinical interpretation as it allows different qualities of information to be combined into a single picture, for example, functional information such as metabolic activity, to be combined with anatomical information showing the precise location of pathology relative to bones and organs. This provides clinical users with a more complete picture, thereby improving the quality of information available when managing a patient's condition. Mirada's products are designed to support the comparison of multi-modal images acquired over any number of follow up visits by the patient, making them particularly well suited to the analysis of treatment response in longer term treatment plans such as those typical when treating cancer.
Mirada Medical was formed out of Oxford University by Professor Sir Michael Brady, one of the world's leading medical imaging scientists. The Company is ISO 13485 certified and its technology has been supplied globally to customers in countries including the US, Japan, and Europe since 2001. Mirada's products are sold by Mirada but also by major healthcare players such as McKesson, Siemens, Sectra, Carestream and Vital Images.
The Mirada team is a combination of world class scientists and exceptional engineers sourced from both Oxford University and leading blue-chip companies. For more information, visit www.mirada-medical.com.
SOURCE: Mirada Medical Limited